These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38500886)

  • 61. Peritumor tertiary lymphoid structures are associated with infiltrating neutrophils and inferior prognosis in hepatocellular carcinoma.
    Zhang T; Lei X; Jia W; Li J; Nie Y; Mao Z; Wang Y; Tao K; Song W
    Cancer Med; 2023 Feb; 12(3):3068-3078. PubMed ID: 36082777
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer.
    Xiao BY; Zhang X; Cao TY; Li DD; Jiang W; Kong LH; Tang JH; Han K; Zhang CZ; Mei WJ; Xiao J; Pan ZZ; Li YF; Zhang XS; Ding PR
    J Natl Compr Canc Netw; 2023 Jan; 21(1):60-66.e5. PubMed ID: 36630898
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma.
    Ma YT; Yang HL; Yan L; Hua F; Wang DG; Xu GY; Li Y; Xue YJ; Qin YJ; Sha D; Ning H; Zhao MQ; Yao ZG
    Pathol Oncol Res; 2022; 28():1610638. PubMed ID: 36338826
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer.
    Ding K; Mou P; Wang Z; Liu S; Liu J; Lu H; Yu G
    Front Immunol; 2023; 14():1298524. PubMed ID: 38187388
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Exploiting tertiary lymphoid structures gene signature to evaluate tumor microenvironment infiltration and immunotherapy response in colorectal cancer.
    Xu Z; Wang Q; Zhang Y; Li X; Wang M; Zhang Y; Pei Y; Li K; Yang M; Luo L; Wu C; Wang W
    Front Oncol; 2024; 14():1383096. PubMed ID: 38846981
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer.
    He Y; Zhang X; Zhu M; He W; Hua H; Ye F; Zhou X; Chen N; Li Y; Zhong W; Wu G; Cai H; Jiang W
    J Transl Med; 2023 Jan; 21(1):25. PubMed ID: 36639643
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series.
    Zhou C; Jiang T; Xiao Y; Wang Q; Zeng Z; Cai P; Zhao Y; Zhao Z; Wu D; Lin H; Sun C; Zhang R; Xiao W; Gao Y
    Front Immunol; 2021; 12():784336. PubMed ID: 34975873
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma.
    Lee LH; Cavalcanti MS; Segal NH; Hechtman JF; Weiser MR; Smith JJ; Garcia-Aguilar J; Sadot E; Ntiamoah P; Markowitz AJ; Shike M; Stadler ZK; Vakiani E; Klimstra DS; Shia J
    Mod Pathol; 2016 Nov; 29(11):1433-1442. PubMed ID: 27443512
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
    Chen X; Yang Z; Feng J; Duan T; Pan T; Yan L; Jin T; Xiang Y; Zhang M; Chen P; Wang W; Zhang R; Chen B; Zhao L; Xie T; Sui X
    Cancer Med; 2021 Jan; 10(1):317-324. PubMed ID: 33174323
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer.
    Yarchoan M; Huang CY; Zhu Q; Ferguson AK; Durham JN; Anders RA; Thompson ED; Rozich NS; Thomas DL; Nauroth JM; Rodriguez C; Osipov A; De Jesus-Acosta A; Le DT; Murphy AG; Laheru D; Donehower RC; Jaffee EM; Zheng L; Azad NS
    Cancer Med; 2020 Feb; 9(4):1485-1494. PubMed ID: 31876399
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13
    Hu C; You W; Kong D; Huang Y; Lu J; Zhao M; Jin Y; Peng R; Hua D; Kuang DM; Chen Y
    Gastroenterology; 2024 Jun; 166(6):1069-1084. PubMed ID: 38445519
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status.
    Ahtiainen M; Wirta EV; Kuopio T; Seppälä T; Rantala J; Mecklin JP; Böhm J
    Mod Pathol; 2019 Jun; 32(6):866-883. PubMed ID: 30723299
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
    Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort.
    Zwart K; van der Baan FH; Punt CJA; Wensink GE; Bolhuis K; Laclé MM; van Grevenstein WMU; Hagendoorn J; de Hingh IH; Koopman M; Vink G; Roodhart J
    Ann Surg Oncol; 2023 Oct; 30(11):6762-6770. PubMed ID: 37528303
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Association between local immune cell infiltration, mismatch repair status and systemic inflammatory response in colorectal cancer.
    Gunnarsson U; Strigård K; Edin S; Gkekas I; Mustonen H; Kaprio T; Böckelman C; Hagström J; Palmqvist R; Haglund C
    J Transl Med; 2020 Apr; 18(1):178. PubMed ID: 32316975
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer.
    Sillo TO; Beggs AD; Middleton G; Akingboye A
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982838
    [TBL] [Abstract][Full Text] [Related]  

  • 77. PD-1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR/MSS colorectal cancer.
    Pei F; He W; Duan Y; Yao Q; Zhao Y; Fan X; Liu S; Chen H; He F; Liu T; Chen J; Zheng Y; Li H; Guo X; Shi L; Ling L; Chen Y; He J; Liu M; Huang M; Bai Y; Wang J; Huang M; Huang J
    Cancer Med; 2024 Jun; 13(12):e7224. PubMed ID: 38888366
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Development of novel models for predicting mismatch repair protein deficiency and relevant disease-free survival in colorectal cancer patients.
    Xu Y; Li Y; Zhu Z; Yang J; Tan Y; Wang Y; Xu X
    Int J Colorectal Dis; 2022 Jun; 37(6):1449-1464. PubMed ID: 35482069
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identifying specific TLS-associated genes as potential biomarkers for predicting prognosis and evaluating the efficacy of immunotherapy in soft tissue sarcoma.
    Wang XX; Liu YP; Lu Y; Wu LH; Ren JY; Ji H; Wang X; Zhang HM
    Front Immunol; 2024; 15():1372692. PubMed ID: 38720884
    [TBL] [Abstract][Full Text] [Related]  

  • 80. BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors.
    Fu Y; Yang B; Cui Y; Hu X; Li X; Lu F; Qin T; Zhang L; Hu Z; Guo E; Fan J; Xiao R; Li W; Qin X; Hu D; Peng W; Liu J; Wang B; Mills GB; Chen G; Sun C
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.